biOasis Information to be Available Through Standard & Poor's Market Access Program

VANCOUVER, British Columbia, July 7, 2009 (GLOBE NEWSWIRE) -- biOasis
Technologies Inc. (TSX.V:BTI) is pleased to announce that its company
information will be made available via Standard & Poor's Market Access Program,
an information distribution service that enables subscribing publicly traded
companies to have their company information disseminated to users of Standard &
Poor's Advisor Insight. The company information to be made available through
this program includes share price, volume, dividends, shares outstanding,
company financial position, and earnings. Standard & Poor's Advisor Insight is
an Internet-based research engine used by more than 100,000 investment advisors.
A public version of the site is available at www.advisorinsight.com.

In addition, information about companies in Standard & Poor's Market Access
Program will be available via S&P's Stock Guide database, which is distributed
electronically to virtually all major quote vendors. As part of the program, a
full description of biOasis Technologies Inc. was published in the Daily News
section of Standard Corporation Records on July 1, 2009, a recognized securities
manual for secondary trading in approximately 38 states under their Blue Sky
Laws.

ABOUT BIOASIS:

biOasis Technologies Inc. is a Canadian Biotechnology company engaged in the
development and commercialization of diagnostics and therapeutics related to
neurological diseases. It has extensive and comprehensive intellectual property
("IP"), which it obtained from the University of British Columbia. The Company's
initial area of focus will be on the utilization of its IP to pursue a biomarker
for the diagnosis of Alzheimer's disease based on quantitation of p97
(melanotransferrin) in blood plasma. The IP has been corroborated in double
blinded and successive multi-site clinical trials. According to the Centers for
Disease Control and Prevention ("CDC"), Alzheimer's disease was listed as the
"underlying cause of death" for 65,829 Americans in 2004. It was the seventh
leading cause of death for people of all ages and the fifth leading cause of
death in people age 65 and older. The Company is also pursuing the use of p97 as
a carrier for delivery of a variety of drugs and other therapeutic molecules
across the Blood Brain Barrier.

To find out more about biOasis Technologies Inc. visit www.bioasis.ca or contact
Rob Hutchison, Chairman and CEO at: telephone (604) 542-5059 or rob@bioasis.ca

Standard and Poor's customer contacts are: Richard Albanese at telephone (212)
438-3647 or richard_albanese@standardandpoors.com or Standard and Poor's Media
Relations Contact: Michael Privitera at telephone (212) 438-6679 or
michael_privitera@standardandpoors.com

Company information distributed through the Market Access Program is based upon
information that Standard & Poor's considers to be reliable, but neither
Standard & Poor's nor its affiliates warrant its completeness or accuracy, and
it should not be relied upon as such. This material is not intended as an offer
or solicitation for the purchase or sale of any security or other financial
instrument.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: we may not be able to successfully develop and
obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's,
or future products in our targeted corporate objectives; our future operating
results are uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be able to
establish marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward-looking statements and information to reflect subsequent events or
circumstances, except as required by law.

On Behalf of the Board of Directors

Robin Hutchison
Chairman and CEO
"The TSX Venture Exchange has neither approved nor disapproved the contents of
this press release."

-0-
CONTACT: biOasis Technologies Inc.
Rob Hutchison, Chairman and CEO
(604) 542-5059
rob@bioasis.ca